Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD)

a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Clinical Evaluator Training Group

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Background Duchenne muscular dystrophy (DMD) is a severe, progressive, and rare neuromuscular, X-linked recessive disease. Dystrophin deficiency is the underlying cause of disease; therefore, mutation-specific therapies aimed at restoring dystrophin protein production are being explored. We aimed to assess the efficacy and safety of ataluren in ambulatory boys with nonsense mutation DMD. Methods We did this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 54 sites in 18 countries located in North America, Europe, the Asia-Pacific region, and Latin America. Boys aged 7–16 years with nonsense mutation DMD and a baseline 6-minute walk distance (6MWD) of 150 m or more and 80% or less of the predicted normal value for age and height were randomly assigned (1:1), via permuted block randomisation (block size of four) using an interactive voice-response or web-response system, to receive ataluren orally three times daily (40 mg/kg per day) or matching placebo. Randomisation was stratified by age (<9 years vs ≥9 years), duration of previous corticosteroid use (6 months to <12 months vs ≥12 months), and baseline 6MWD (<350 m vs ≥350 m). Patients, parents and caregivers, investigational site personnel, PTC Therapeutics employees, and all other study personnel were masked to group allocation until after database lock. The primary endpoint was change in 6MWD from baseline to week 48. We additionally did a prespecified subgroup analysis of the primary endpoint, based on baseline 6MWD, which is reflective of anticipated rates of disease progression over 1 year. The primary analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01826487. Findings Between March 26, 2013, and Aug 26, 2014, we randomly assigned 230 patients to receive ataluren (n=115) or placebo (n=115); 228 patients comprised the intention-to-treat population. The least-squares mean change in 6MWD from baseline to week 48 was −47·7 m (SE 9·3) for ataluren-treated patients and −60·7 m (9·3) for placebo-treated patients (difference 13·0 m [SE 10·4], 95% CI −7·4 to 33·4; p=0·213). The least-squares mean change for ataluren versus placebo in the prespecified subgroups was −7·7 m (SE 24·1, 95% CI −54·9 to 39·5; p=0·749) in the group with a 6MWD of less than 300 m, 42·9 m (15·9, 11·8–74·0; p=0·007) in the group with a 6MWD of 300 m or more to less than 400 m, and −9·5 m (17·2, −43·2 to 24·2; p=0·580) in the group with a 6MWD of 400 m or more. Ataluren was generally well tolerated and most treatment-emergent adverse events were mild to moderate in severity. Eight (3%) patients (n=4 per group) reported serious adverse events; all except one event in the placebo group (abnormal hepatic function deemed possibly related to treatment) were deemed unrelated to treatment. Interpretation Change in 6MWD did not differ significantly between patients in the ataluren group and those in the placebo group, neither in the intention-to-treat population nor in the prespecified subgroups with a baseline 6MWD of less than 300 m or 400 m or more. However, we recorded a significant effect of ataluren in the prespecified subgroup of patients with a baseline 6MWD of 300 m or more to less than 400 m. Baseline 6MWD values within this range were associated with a more predictable rate of decline over 1 year; this finding has implications for the design of future DMD trials with the 6-minute walk test as the endpoint. Funding PTC Therapeutics.

Original languageEnglish (US)
Pages (from-to)1489-1498
Number of pages10
JournalThe Lancet
Volume390
Issue number10101
DOIs
StatePublished - Sep 23 2017

Fingerprint

Duchenne Muscular Dystrophy
Nonsense Codon
Placebos
Dystrophin
Factor IX
Random Allocation
Least-Squares Analysis
Therapeutics
Intention to Treat Analysis
Latin America
ataluren
North America
Caregivers
Population
Disease Progression
Adrenal Cortex Hormones
Reference Values
Parents
Databases
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD) : a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. / Clinical Evaluator Training Group.

In: The Lancet, Vol. 390, No. 10101, 23.09.2017, p. 1489-1498.

Research output: Contribution to journalArticle

@article{7e9b6e835ba244ec97bf50d653fc1cc3,
title = "Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial",
abstract = "Background Duchenne muscular dystrophy (DMD) is a severe, progressive, and rare neuromuscular, X-linked recessive disease. Dystrophin deficiency is the underlying cause of disease; therefore, mutation-specific therapies aimed at restoring dystrophin protein production are being explored. We aimed to assess the efficacy and safety of ataluren in ambulatory boys with nonsense mutation DMD. Methods We did this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 54 sites in 18 countries located in North America, Europe, the Asia-Pacific region, and Latin America. Boys aged 7–16 years with nonsense mutation DMD and a baseline 6-minute walk distance (6MWD) of 150 m or more and 80{\%} or less of the predicted normal value for age and height were randomly assigned (1:1), via permuted block randomisation (block size of four) using an interactive voice-response or web-response system, to receive ataluren orally three times daily (40 mg/kg per day) or matching placebo. Randomisation was stratified by age (<9 years vs ≥9 years), duration of previous corticosteroid use (6 months to <12 months vs ≥12 months), and baseline 6MWD (<350 m vs ≥350 m). Patients, parents and caregivers, investigational site personnel, PTC Therapeutics employees, and all other study personnel were masked to group allocation until after database lock. The primary endpoint was change in 6MWD from baseline to week 48. We additionally did a prespecified subgroup analysis of the primary endpoint, based on baseline 6MWD, which is reflective of anticipated rates of disease progression over 1 year. The primary analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01826487. Findings Between March 26, 2013, and Aug 26, 2014, we randomly assigned 230 patients to receive ataluren (n=115) or placebo (n=115); 228 patients comprised the intention-to-treat population. The least-squares mean change in 6MWD from baseline to week 48 was −47·7 m (SE 9·3) for ataluren-treated patients and −60·7 m (9·3) for placebo-treated patients (difference 13·0 m [SE 10·4], 95{\%} CI −7·4 to 33·4; p=0·213). The least-squares mean change for ataluren versus placebo in the prespecified subgroups was −7·7 m (SE 24·1, 95{\%} CI −54·9 to 39·5; p=0·749) in the group with a 6MWD of less than 300 m, 42·9 m (15·9, 11·8–74·0; p=0·007) in the group with a 6MWD of 300 m or more to less than 400 m, and −9·5 m (17·2, −43·2 to 24·2; p=0·580) in the group with a 6MWD of 400 m or more. Ataluren was generally well tolerated and most treatment-emergent adverse events were mild to moderate in severity. Eight (3{\%}) patients (n=4 per group) reported serious adverse events; all except one event in the placebo group (abnormal hepatic function deemed possibly related to treatment) were deemed unrelated to treatment. Interpretation Change in 6MWD did not differ significantly between patients in the ataluren group and those in the placebo group, neither in the intention-to-treat population nor in the prespecified subgroups with a baseline 6MWD of less than 300 m or 400 m or more. However, we recorded a significant effect of ataluren in the prespecified subgroup of patients with a baseline 6MWD of 300 m or more to less than 400 m. Baseline 6MWD values within this range were associated with a more predictable rate of decline over 1 year; this finding has implications for the design of future DMD trials with the 6-minute walk test as the endpoint. Funding PTC Therapeutics.",
author = "{Clinical Evaluator Training Group} and McDonald, {Craig M.} and Craig Campbell and Torricelli, {Ricardo Erazo} and Finkel, {Richard S.} and Flanigan, {Kevin M.} and Nathalie Goemans and Peter Heydemann and Anna Kaminska and Janbernd Kirschner and Francesco Muntoni and Osorio, {Andr{\'e}s Nascimento} and Ulrike Schara and Thomas Sejersen and Shieh, {Perry B.} and Sweeney, {H. Lee} and Haluk Topaloglu and M{\'a}r Tulinius and Vilchez, {Juan J.} and Thomas Voit and Brenda Wong and Gary Elfring and Hans Kroger and Xiaohui Luo and Joseph McIntosh and Tuyen Ong and Peter Riebling and Marcio Souza and Spiegel, {Robert J.} and Peltz, {Stuart W.} and Eugenio Mercuri and Alfano, {Lindsay N.} and Michelle Eagle and James, {Meredith K.} and Linda Lowes and Anna Mayhew and Mazzone, {Elena S.} and Leslie Nelson and Rose, {Kristy J.} and Abdel-Hamid, {Hoda Z.} and Apkon, {Susan D.} and Barohn, {Richard J.} and Enrico Bertini and Clemens Bloetzer and {de Vaud}, {Lausanne Canton} and Butterfield, {Russell J.} and Brigitte Chabrol and Chae, {Jong Hee} and Jongno-gu, {Daehak ro} and Comi, {Giacomi Pietro} and Iannaccone, {Susan T.}",
year = "2017",
month = "9",
day = "23",
doi = "10.1016/S0140-6736(17)31611-2",
language = "English (US)",
volume = "390",
pages = "1489--1498",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "10101",

}

TY - JOUR

T1 - Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD)

T2 - a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

AU - Clinical Evaluator Training Group

AU - McDonald, Craig M.

AU - Campbell, Craig

AU - Torricelli, Ricardo Erazo

AU - Finkel, Richard S.

AU - Flanigan, Kevin M.

AU - Goemans, Nathalie

AU - Heydemann, Peter

AU - Kaminska, Anna

AU - Kirschner, Janbernd

AU - Muntoni, Francesco

AU - Osorio, Andrés Nascimento

AU - Schara, Ulrike

AU - Sejersen, Thomas

AU - Shieh, Perry B.

AU - Sweeney, H. Lee

AU - Topaloglu, Haluk

AU - Tulinius, Már

AU - Vilchez, Juan J.

AU - Voit, Thomas

AU - Wong, Brenda

AU - Elfring, Gary

AU - Kroger, Hans

AU - Luo, Xiaohui

AU - McIntosh, Joseph

AU - Ong, Tuyen

AU - Riebling, Peter

AU - Souza, Marcio

AU - Spiegel, Robert J.

AU - Peltz, Stuart W.

AU - Mercuri, Eugenio

AU - Alfano, Lindsay N.

AU - Eagle, Michelle

AU - James, Meredith K.

AU - Lowes, Linda

AU - Mayhew, Anna

AU - Mazzone, Elena S.

AU - Nelson, Leslie

AU - Rose, Kristy J.

AU - Abdel-Hamid, Hoda Z.

AU - Apkon, Susan D.

AU - Barohn, Richard J.

AU - Bertini, Enrico

AU - Bloetzer, Clemens

AU - de Vaud, Lausanne Canton

AU - Butterfield, Russell J.

AU - Chabrol, Brigitte

AU - Chae, Jong Hee

AU - Jongno-gu, Daehak ro

AU - Comi, Giacomi Pietro

AU - Iannaccone, Susan T.

PY - 2017/9/23

Y1 - 2017/9/23

N2 - Background Duchenne muscular dystrophy (DMD) is a severe, progressive, and rare neuromuscular, X-linked recessive disease. Dystrophin deficiency is the underlying cause of disease; therefore, mutation-specific therapies aimed at restoring dystrophin protein production are being explored. We aimed to assess the efficacy and safety of ataluren in ambulatory boys with nonsense mutation DMD. Methods We did this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 54 sites in 18 countries located in North America, Europe, the Asia-Pacific region, and Latin America. Boys aged 7–16 years with nonsense mutation DMD and a baseline 6-minute walk distance (6MWD) of 150 m or more and 80% or less of the predicted normal value for age and height were randomly assigned (1:1), via permuted block randomisation (block size of four) using an interactive voice-response or web-response system, to receive ataluren orally three times daily (40 mg/kg per day) or matching placebo. Randomisation was stratified by age (<9 years vs ≥9 years), duration of previous corticosteroid use (6 months to <12 months vs ≥12 months), and baseline 6MWD (<350 m vs ≥350 m). Patients, parents and caregivers, investigational site personnel, PTC Therapeutics employees, and all other study personnel were masked to group allocation until after database lock. The primary endpoint was change in 6MWD from baseline to week 48. We additionally did a prespecified subgroup analysis of the primary endpoint, based on baseline 6MWD, which is reflective of anticipated rates of disease progression over 1 year. The primary analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01826487. Findings Between March 26, 2013, and Aug 26, 2014, we randomly assigned 230 patients to receive ataluren (n=115) or placebo (n=115); 228 patients comprised the intention-to-treat population. The least-squares mean change in 6MWD from baseline to week 48 was −47·7 m (SE 9·3) for ataluren-treated patients and −60·7 m (9·3) for placebo-treated patients (difference 13·0 m [SE 10·4], 95% CI −7·4 to 33·4; p=0·213). The least-squares mean change for ataluren versus placebo in the prespecified subgroups was −7·7 m (SE 24·1, 95% CI −54·9 to 39·5; p=0·749) in the group with a 6MWD of less than 300 m, 42·9 m (15·9, 11·8–74·0; p=0·007) in the group with a 6MWD of 300 m or more to less than 400 m, and −9·5 m (17·2, −43·2 to 24·2; p=0·580) in the group with a 6MWD of 400 m or more. Ataluren was generally well tolerated and most treatment-emergent adverse events were mild to moderate in severity. Eight (3%) patients (n=4 per group) reported serious adverse events; all except one event in the placebo group (abnormal hepatic function deemed possibly related to treatment) were deemed unrelated to treatment. Interpretation Change in 6MWD did not differ significantly between patients in the ataluren group and those in the placebo group, neither in the intention-to-treat population nor in the prespecified subgroups with a baseline 6MWD of less than 300 m or 400 m or more. However, we recorded a significant effect of ataluren in the prespecified subgroup of patients with a baseline 6MWD of 300 m or more to less than 400 m. Baseline 6MWD values within this range were associated with a more predictable rate of decline over 1 year; this finding has implications for the design of future DMD trials with the 6-minute walk test as the endpoint. Funding PTC Therapeutics.

AB - Background Duchenne muscular dystrophy (DMD) is a severe, progressive, and rare neuromuscular, X-linked recessive disease. Dystrophin deficiency is the underlying cause of disease; therefore, mutation-specific therapies aimed at restoring dystrophin protein production are being explored. We aimed to assess the efficacy and safety of ataluren in ambulatory boys with nonsense mutation DMD. Methods We did this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 54 sites in 18 countries located in North America, Europe, the Asia-Pacific region, and Latin America. Boys aged 7–16 years with nonsense mutation DMD and a baseline 6-minute walk distance (6MWD) of 150 m or more and 80% or less of the predicted normal value for age and height were randomly assigned (1:1), via permuted block randomisation (block size of four) using an interactive voice-response or web-response system, to receive ataluren orally three times daily (40 mg/kg per day) or matching placebo. Randomisation was stratified by age (<9 years vs ≥9 years), duration of previous corticosteroid use (6 months to <12 months vs ≥12 months), and baseline 6MWD (<350 m vs ≥350 m). Patients, parents and caregivers, investigational site personnel, PTC Therapeutics employees, and all other study personnel were masked to group allocation until after database lock. The primary endpoint was change in 6MWD from baseline to week 48. We additionally did a prespecified subgroup analysis of the primary endpoint, based on baseline 6MWD, which is reflective of anticipated rates of disease progression over 1 year. The primary analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01826487. Findings Between March 26, 2013, and Aug 26, 2014, we randomly assigned 230 patients to receive ataluren (n=115) or placebo (n=115); 228 patients comprised the intention-to-treat population. The least-squares mean change in 6MWD from baseline to week 48 was −47·7 m (SE 9·3) for ataluren-treated patients and −60·7 m (9·3) for placebo-treated patients (difference 13·0 m [SE 10·4], 95% CI −7·4 to 33·4; p=0·213). The least-squares mean change for ataluren versus placebo in the prespecified subgroups was −7·7 m (SE 24·1, 95% CI −54·9 to 39·5; p=0·749) in the group with a 6MWD of less than 300 m, 42·9 m (15·9, 11·8–74·0; p=0·007) in the group with a 6MWD of 300 m or more to less than 400 m, and −9·5 m (17·2, −43·2 to 24·2; p=0·580) in the group with a 6MWD of 400 m or more. Ataluren was generally well tolerated and most treatment-emergent adverse events were mild to moderate in severity. Eight (3%) patients (n=4 per group) reported serious adverse events; all except one event in the placebo group (abnormal hepatic function deemed possibly related to treatment) were deemed unrelated to treatment. Interpretation Change in 6MWD did not differ significantly between patients in the ataluren group and those in the placebo group, neither in the intention-to-treat population nor in the prespecified subgroups with a baseline 6MWD of less than 300 m or 400 m or more. However, we recorded a significant effect of ataluren in the prespecified subgroup of patients with a baseline 6MWD of 300 m or more to less than 400 m. Baseline 6MWD values within this range were associated with a more predictable rate of decline over 1 year; this finding has implications for the design of future DMD trials with the 6-minute walk test as the endpoint. Funding PTC Therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=85024501735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024501735&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(17)31611-2

DO - 10.1016/S0140-6736(17)31611-2

M3 - Article

VL - 390

SP - 1489

EP - 1498

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10101

ER -